| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | President & CEO | SVP, Advanced Diagnostics
3 companies
Manner Carrie Eglinton is President & CEO at OSUR, with reported holdings spanning 3 companies. Manner Carrie Eglinton's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $20.7M at current prices.
Our model assigns Manner Carrie Eglinton a below-average insider score of 45/100, based on 5 past trades. Over a 12-month horizon, 33.3% of those trades were profitable, with an average 12-month return of -3.6%.
Manner Carrie Eglinton's largest disclosed position is in DGX as SVP, Advanced Diagnostics, worth about $12.0M. The DGX filings lean toward selling, a net 5,000 shares.
Manner Carrie Eglinton has 41 Form 4 filings on record from February 2017 to May 2026, across 3 companies: Director at Repligen (RGEN), 2020–2026; President & CEO at OraSure Technologies (OSUR), 2022–2026; SVP, Advanced Diagnostics at Quest Diagnostics (DGX), 2017–2022.
The 69 reported transactions were 25 tax withholdings, 24 stock awards, 13 option or other derivative awards and 5 open-market purchases, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 5 purchases worth about $617K and 1 sale worth about $555K.
The largest open-market purchase was 78,625 shares of OSUR at an average $3.15 on February 27, 2025, about $247K. Twelve months later OSUR was up 1%.
The only open-market sale was 5,000 shares of DGX at an average $111.02 on April 27, 2020, about $555K.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 20, 2026 | OSUR Orasure Technologies, Inc. | President & CEO | Buy10b5-1 | 32,300 | $2.93 | $94,597.01 | +1.5% | +44.1% | - | |
| Mar 13, 2026 | OSUR Orasure Technologies, Inc. | President & CEO | Buy10b5-1 | 22,022 | $3.00 | $66,032.97 | +1.0% | +41.1% | - | |
| Feb 28, 2025 | OSUR Orasure Technologies Inc | President & CEO | Buy | 28,670 | $3.49 | $100,026.76 | +2.3% | -18.4% | -9.5% | |
| Feb 27, 2025 | OSUR Orasure Technologies Inc | President & CEO | Buy | 78,625 | $3.15 | $247,377.84 | +6.7% | -11.5% | +0.6% | |
| Mar 16, 2022 | RGEN Repligen Corp | Director | Buy | 625 | $175.02 | $109,387.50 | +42.2% | -19.3% | -1.9% | |
| Apr 27, 2020 | DGX Quest Diagnostics Inc | SVP, Advanced Diagnostics | Sell | 5,000 | $111.02 | $555,075.00 | -18.3% | - | - |